Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 2Recruiting 1

Sponsor Class

INDUSTRY 3OTHER 2NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1Classical hematology 1

Conditions

Neoplasms 30Prostatic Neoplasms 22Neoplasm Metastasis 20Breast Neoplasms 17Lung Neoplasms 16Colorectal Neoplasms 15Leukemia, Myeloid, Acute 14Pancreatic Neoplasms 13Ovarian Neoplasms 12Urinary Bladder Neoplasms 11Lymphoma 11Hematologic Neoplasms 11Carcinoma, Non-Small-Cell Lung 10Stomach Neoplasms 9Myelodysplastic Syndromes 9Squamous Cell Carcinoma of Head and Neck 8Sarcoma, Kaposi 8Pheochromocytoma 8Multiple Myeloma 8Melanoma 8Lymphoma, Non-Hodgkin 8Leukemia, Lymphocytic, Chronic, B-Cell 8Endometrial Neoplasms 8Carcinoma, Renal Cell 8Burkitt Lymphoma 8Neuroendocrine Tumors 7Mouth Neoplasms 7Kidney Neoplasms 7Glioma 7Thyroid Neoplasms 6

Interventions

11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × NIH × Bone Marrow Diseases × Clear all
NCT06303193 2026-06-05

Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms

National Institutes of Health Clinical Center (CC)

Phase 1/2 Recruiting
160 enrolled
Classical hematologyMyeloid

Anemia, Aplastic, Anemia, Refractory, with Excess of Blasts, Bone Marrow Diseases, Myelodysplastic Syndromes, Myeloproliferative Disorders

Data powered by HemOnc (CC BY 4.0) Colophon âš¡